top of page
Asian Institute of Research, Journal Publication, Journal Academics, Education Journal, Asian Institute
Asian Institute of Research, Journal Publication, Journal Academics, Education Journal, Asian Institute

Economics and Business

Quarterly Reviews

ISSN 2775-9237 (Online)

asian institute research, jeb, journal of economics and business, economics journal, accunting journal, business journal, managemet journal
asian institute research, jeb, journal of economics and business, economics journal, accunting journal, business journal, managemet journal
asian institute research, jeb, journal of economics and business, economics journal, accunting journal, business journal, managemet journal
asian institute research, jeb, journal of economics and business, economics journal, accunting journal, business journal, managemet journal
crossref
doi
open access

Published: 26 May 2020

Focus, Asset Tangibility and Value Creation in M&A Transactions: Evidence from the Pharmaceutical Industry

Christian Wieber, Dirk Schiereck

Technical University of Darmstadt, Germany

asian institute research, jeb, journal of economics and business, economics journal, accunting journal, business journal, management journal

Download Full-Text Pdf

doi

10.31014/aior.1992.03.02.235

Pages: 734-759

Keywords: Pharmaceutical Industry, Mergers and Acquisitions, Takeovers, Specialization, Diversification, R&D, Asset Deals, M&A Waves, Event Study, Abnormal Returns, Propensity Score Matching

Abstract

Through mergers and acquisitions the pharmaceutical industry has changed in the last years like never before. The widespread paradigm that acquirers face negative returns at acquisition announcement, resulting in significant losses, no longer applies. Including the largest consolidation wave in 2013 to 2016, we find overarching highly positive returns for acquirers, targets and combined entities. With a differentiated analysis approach of categorizing events in specialization, diversification and R&D-driven acquisitions based on the acquirer and target’s business model, we are able to assess intra-industry M&A success drivers holistically and from a completely new angle. Not only are we seeing specialization acquisitions from an acquirer perspective outperform the other two types by around 2%, but also targets in R&D-related acquisitions face an increase of roughly 50%, more than two times of the other groups’ returns. Furthermore, the results highlight that acquirers earn the highest returns in asset deal transactions, while the sellers are worse off. Finally, we see the largest M&A wave in the industry ever since leads to positive and superior reactions of around 3%. In parallel, the tense market situation results in a paradigm shift not only for the affected M&A parties, but for the competitors as well. Where there was a parallel movement of the acquirers’ and competitors’ abnormal announcement returns in the early years of the millennium, there now is a shift in the opposite direction, meaning that good news for the acquirer now implies bad news for the competitor.

References

  1. Aitken, Murray; Kleinrock, Michael (2015): Global Medicines Use in 2020. Outlook and Implications. Retrieved from: https://s3.amazonaws.com/assets.fiercemarkets.net/public/005-LifeSciences/imsglobalreport.pdf.

  2. Alexandridis, G.; Antypas, N.; Travlos, N. (2017): Value creation from M&As. New evidence. In: Journal of Corporate Finance 45, P. 632–650.

  3. Alexandridis, George; Fuller, Kathleen P.; Terhaar, Lars; Travlos, Nickolaos G. (2013): Deal size, acquisition premia and shareholder gains. In: Journal of Corporate Finance 20, P. 1–13.

  4. Andrade, Gregor M-M.; Stafford, Erik (2004): Investigating the economic role of mergers. In: Journal of Corporate Finance 10 (1), P. 1–36.

  5. Banerjee, Tannista; Siebert, Ralph (2017-1): The Impact of R&D Cooperations and Mergers in Pharmaceuticals on Research Activities and Drugs Offered on the Market. In: Southern Economic Journal 84 (1), P. 202–228.

  6. Banerjee, Tannista; Siebert, Ralph (2017-2): Dynamic impact of uncertainty on R&D cooperation formation and research performance. Evidence from the bio-pharmaceutical industry. In: Research Policy 46 (7), P. 1255–1271.

  7. Bargeron, Leonce; Schlingemann, Frederik P.; Stulz, René M.; Zutter, Chad (2007): Why Do Private Acquirers Pay So Little Compared to Public Acquirers? Cambridge, MA: National Bureau of Economic Research.

  8. Barrow, David; Kleinz, Matthias; Gladstone, Micheal; Jacquet, Pierre (2012): Too Big To Succeed: Where Are Large Pharmas Heading? In: IN VIVO 30 (11), P. 70–75.

  9. Berger, Philip G.; Ofek, Eli (1995): Diversification's effect on firm value. In: Journal of Financial Economics 37 (1), P. 39–65.

  10. Biggadike, Ralph (1979): The Risky Business of Diversification. In: Harvard Business Review 57 (3), P. 103–111.

  11. Boehmer, Ekkehart; Poulsen, Annette; Musumeci, Jim J. (1991): Event study methodology under conditions of event-induced variance. In: Journal of Financial Economics 30 (2), P. 253–272.

  12. Borisova, Ginka; John, Kose; Salotti, Valentina (2013): The value of financing through cross-border asset sales. Shareholder returns and liquidity. In: Journal of Corporate Finance 22, P. 320–344.

  13. Bruner, Robert F. (2002): Does M&A Pay? A Survey of Evidence for the Decision-Maker. In: Journal of Applied Finance 12 (1), P. 48–68.

  14. Cai, Jie; Song, Moon H.; Walkling, Ralph A. (2011): Anticipation, Acquisitions, and Bidder Returns. Industry Shocks and the Transfer of Information across Rivals. In: Review of Financial Studies 24 (7), P. 2242–2285.

  15. Caliendo, Marco; Kopeinig, Sabine (2008): Some Practical Guidance for the Implementation of Propensity Score Matching. In: Journal of Economic Surveys 22 (1), P. 31–72.

  16. Campbell, John Y.; Lo, Andrew W.; MacKinlay, A. Craig (1997): The econometrics of financial markets. Princeton, NJ: Princeton Univ. Press.

  17. Chang, Saeyoung (1998): Takeovers of Privately Held Targets, Methods of Payment, and Bidder Returns. In: The Journal of Finance 53 (2), P. 773–784.

  18. Clayton, Matthew J.; Reisel, Natalia (2013): Value creation from asset sales. New evidence from bond and stock markets. In: Journal of Corporate Finance 22, P. 1–15.

  19. Comment, Robert; Jarrell, Gregg A. (1995): Corporate focus and stock returns. In: Journal of Financial Economics 37 (1), P. 67–87.

  20. Corrado, Charles J. (2011): Event studies: A methodology review. In: Accounting & Finance 51 (1), P. 207–234.

  21. Corrado, Charles J.; Zivney, Terry L. (1992): The Specification and Power of the Sign Test in Event Study Hypothesis Tests Using Daily Stock Returns. In: The Journal of Financial and Quantitative Analysis 27 (3), P. 465.

  22. Danzon, Patricia M.; Epstein, Andrew; Nicholson, Sean (2007): Mergers and acquisitions in the pharmaceutical and biotech industries. In: Managerial and Decision Economics 28 (4-5), P. 307–328.

  23. DiMasi, Joseph A.; Grabowski, Henry G.; Hansen, Ronald W. (2016): Innovation in the pharmaceutical industry. New estimates of R&D costs. In: Journal of Health Economics 47, P. 20–33.

  24. Dimopoulos, Theodosios; Sacchetto, Stefano (2014): Preemptive bidding, target resistance, and takeover premiums. In: Journal of Financial Economics 114 (3), P. 444–470.

  25. Eckbo, B. Espen (1983): Horizontal mergers, collusion, and stockholder wealth. In: Journal of Financial Economics 11 (1-4), P. 241–273.

  26. Eckbo, B. Espen (1985): Mergers and the Market Concentration Doctrine. Evidence from the Capital Market. In: The Journal of Business 58 (3), P. 325.

  27. Eckbo, B. Espen; Giammarino, Ronald M.; Heinkel, Robert L. (1990): Asymmetric Information and the Medium of Exchange in Takeovers. Theory and Tests. In: Review of Financial Studies 3 (4), P. 651–675.

  28. Erel, Isil; Liao, Rose C.; Weisbach, Michael S. (2012): Determinants of Cross-Border Mergers and Acquisitions. In: The Journal of Finance 67 (3), P. 1045–1082.

  29. Fee, C. Edward; Thomas, Shawn (2004): Sources of gains in horizontal mergers. Evidence from customer, supplier, and rival firms. In: Journal of Financial Economics 74 (3), P. 423–460.

  30. Feyzrakhmanova, Martina; G